MeiraGTx (MGTX) to Release Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX - Get Free Report) is expected to be posting its quarterly earnings results on Thursday, March 13th. Analysts expect MeiraGTx to post earnings of ($0.48) per share for the quarter.

MeiraGTx Stock Down 1.2 %

Shares of NASDAQ:MGTX traded down $0.08 during mid-day trading on Friday, hitting $6.38. 188,285 shares of the company traded hands, compared to its average volume of 233,468. The stock has a market cap of $498.62 million, a P/E ratio of -5.27, a P/E/G ratio of 0.37 and a beta of 1.23. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. MeiraGTx has a 12-month low of $3.85 and a 12-month high of $7.80. The stock has a 50-day moving average price of $6.46 and a two-hundred day moving average price of $5.72.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Chardan Capital reaffirmed a "buy" rating and set a $36.00 target price on shares of MeiraGTx in a research report on Monday, February 24th. Royal Bank of Canada lifted their target price on MeiraGTx from $9.00 to $11.00 and gave the company an "outperform" rating in a research report on Thursday, November 14th.

Insiders Place Their Bets

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the business's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the transaction, the chief executive officer now owns 1,395,102 shares of the company's stock, valued at approximately $9,026,309.94. The trade was a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Richard Giroux sold 24,000 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. This represents a 2.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.40% of the company's stock.

Remove Ads

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.